Fulcrum to merge with Slate in all-stock deal after drug setback
Fulcrum Therapeutics(US:FULC) Reuters·2026-08-17 20:43公司战略与交易 - Fulcrum Therapeutics与私营公司Slate Medicines将以全股票交易方式合并 [1] - 该合并旨在帮助Fulcrum Therapeutics重建其研发管线 [1] - Fulcrum Therapeutics在上个月停止了其主要候选药物的开发 [1]